A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. [electronic resource]
Producer: 20050719Description: 417-23 p. digitalISSN:- 0315-162X
- Acetates -- adverse effects
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Animals
- Antirheumatic Agents -- adverse effects
- Arthritis, Rheumatoid -- drug therapy
- Double-Blind Method
- Enzyme Inhibitors -- adverse effects
- Female
- Humans
- Indoles -- adverse effects
- Keto Acids
- Middle Aged
- Phospholipases A -- antagonists & inhibitors
- Phospholipases A2
- Placebos
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.